US biotech Gilead Sciences (Nasdaq: GILD) announced its financial results for the fourth quarter and full year 2021 after markets closed on Tuesday.
Total fourth quarter 2021 revenue of $7.2 billion decreased 2% compared to the same period in 2020, due to decreased demand for COVID-19 antiviral Veklury (remdesivir), partially offset by favorable pricing dynamics in HIV. However, total sales beat consensus forecast of $6.7 billion. Gilead’s shares fell 3.1% to $66.30 after-hours, but edged back 3.6% to $66.00 in pre-market trading today.
Diluted earnings per share (EPS) plunge to $0.30 for the fourth quarter 2021 compared to $1.23 for the same period in 2020. Non-generally accepted practice (GAAP) diluted EPS decreased to $0.69 for the fourth quarter 2021 compared to $2.19 for the same period in 2020, well below the $1.59 expected by FactSet.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze